These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 33152277

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial.
    Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, Baaijens MH, Bogaerts J, Bartelink H.
    Lancet Oncol; 2012 Apr; 13(4):412-9. PubMed ID: 22373563
    [Abstract] [Full Text] [Related]

  • 25. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, Barrett-Lee P, Ritchie D, Liversedge V, Hinsley S, Marshall H, AZURE investigators.
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [Abstract] [Full Text] [Related]

  • 26. Local recurrences and distant metastases after breast-conserving surgery and radiation therapy for early breast cancer.
    Touboul E, Buffat L, Belkacémi Y, Lefranc JP, Uzan S, Lhuillier P, Faivre C, Huart J, Lotz JP, Antoine M, Pène F, Blondon J, Izrael V, Laugier A, Schlienger M, Housset M.
    Int J Radiat Oncol Biol Phys; 1999 Jan 01; 43(1):25-38. PubMed ID: 9989511
    [Abstract] [Full Text] [Related]

  • 27. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbé C, Ferraresi V, Smylie M, Weber JS, Maio M, Konto C, Hoos A, de Pril V, Gurunath RK, de Schaetzen G, Suciu S, Testori A.
    Lancet Oncol; 2015 May 01; 16(5):522-30. PubMed ID: 25840693
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, Győrffy B, Kásler M, Mátrai Z.
    Eur J Surg Oncol; 2017 Apr 01; 43(4):672-679. PubMed ID: 28139362
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Adjuvant medial versus entire supraclavicular lymph node irradiation in high-risk early breast cancer (SUCLANODE): a protocol for a multicenter, randomized, open-label, phase 3 trial.
    Zhang L, Mei X, Hu Z, Yu B, Zhang C, Li Y, Liu K, Ma X, Ma J, Chen X, Meng J, Shi W, Wang X, Mo M, Shao Z, Zhang Z, Yu X, Guo X, Yang Z.
    BMC Cancer; 2024 Jan 09; 24(1):49. PubMed ID: 38195438
    [Abstract] [Full Text] [Related]

  • 33. Quality-of-life results for accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation in early breast cancer after breast-conserving surgery (GEC-ESTRO): 5-year results of a randomised, phase 3 trial.
    Schäfer R, Strnad V, Polgár C, Uter W, Hildebrandt G, Ott OJ, Kauer-Dorner D, Knauerhase H, Major T, Lyczek J, Guinot JL, Dunst J, Miguelez CG, Slampa P, Allgäuer M, Lössl K, Kovács G, Fischedick AR, Fietkau R, Resch A, Kulik A, Arribas L, Niehoff P, Guedea F, Schlamann A, Gall C, Polat B, Groupe Européen de Curiethérapie of European Society for Radiotherapy and Oncology (GEC-ESTRO).
    Lancet Oncol; 2018 Jun 09; 19(6):834-844. PubMed ID: 29695348
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation.
    Mignano JE, Zahurak ML, Chakravarthy A, Piantadosi S, Dooley WC, Gage I.
    Cancer; 1999 Oct 01; 86(7):1258-62. PubMed ID: 10506712
    [Abstract] [Full Text] [Related]

  • 40. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
    Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP, Jin J, Liu XF, Yu ZH, Ren H, Li N, Lu NN, Tang Y, Tang Y, Qi SN, Sun GY, Peng R, Li S, Chen B, Yang Y, Li YX.
    Lancet Oncol; 2019 Mar 01; 20(3):352-360. PubMed ID: 30711522
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.